Efficient production of first in class antimicrobial therapeutics from an integrated synthetic biology approach

通过综合合成生物学方法高效生产一流的抗菌疗法

• 批准号: BB/M01830X/1
• 负责人: Mathew Upton
• 金额: $ 27.8万
• 依托单位: Plymouth University
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=BB%2FM01830X%2F1
• 关键词: Efficient; production; first; class; antimicrobial

Antibiotic resistant bacteria kill over 25,000 people a year in Europe and threaten a return to a time when minor infections can be fatal and routine surgery poses high risks. With development pipelines empty, there is a critical need for novel therapies to kill antibiotic resistant bacteria and serve as scaffolds for derivatisation, diversification and enhancement of efficacy, which proved successful with drugs like penicillin. Epidermicins are an exciting new class of antimicrobial biologics (ABs) that rapidly kill bacteria, at very low doses and have great potential to prevent or treat bacterial infections including those caused by resistant bacteria. However, the development of the epidermicins is greatly hampered by their very low production in the native host and synthetic production would be prohibitively expensive. This project aims to develop efficient, scalable microbial production systems for epidermicins, enabling their development into a new platform of effective antibiotics.

在欧洲，耐药细菌每年导致超过2.5万人死亡，并有可能重返轻微感染可能致命、常规手术构成高风险的时代。在研发管道空荡荡的情况下，迫切需要新的疗法来杀死抗生素耐药性细菌，并作为衍生化、多样化和增强疗效的支架，这在青霉素等药物中被证明是成功的。表观霉素是一类令人兴奋的新型抗菌生物制品(ABS)，它能以极低的剂量快速杀灭细菌，并具有预防或治疗细菌感染的巨大潜力，包括由耐药细菌引起的感染。然而，由于其在天然宿主中的产量非常低，并且合成生产将是令人望而却步的，因此表皮霉素的开发受到了极大的阻碍。该项目旨在开发高效、可扩展的表皮霉素微生物生产系统，使其发展成为有效抗生素的新平台。